Navigation Links
Prenatal multivitamins reduce birth defects

As per the results of a Canadian study, a multivitamin pill should be taken daily by all women of childbearing age to reduce risks of having a child with birth defects.//

According to the study, the possibility of a wide range of severe birth defects like neural tube defects such as spina bifida, brain-damaging hydrocephalus, heart malformations, truncated or missing limbs, urinary-tract abnormalities and cleft palate can be drastically reduced by ensuring an adequate intake of vitamins and minerals by taking a single, inexpensive pill on a daily basis.

"The data are really very striking. It seems almost too good to be true that a prenatal multivitamin can have such an impact. But it is true," Gideon Koren, director of the Motherisk Program at the Toronto Hospital for Sick Children, said in an interview.

It is already known from previous study that increase in folic acid levels in the diet of a pregnant woman with supplements and fortification of foods could virtually eliminate horrific birth defects such as spina bifida.

However, a far more wide-ranging effect from prenatal multivitamins is revealed in this study published in yesterday’s edition of the Journal of Obstetrics and Gynaecology of Canada.

"This is more than folic acid and it's not just spina bifida," Dr. Koren said. Based on the study, he said, “All women of childbearing age should be taking a prenatal vitamin daily. Because half of all pregnancies are unplanned and almost all birth defects develop in the first trimester.”

However, a specific prenatal multivitamin should be taken by them, he said. Prenatal multivitamins differ from the standard multivitamins in 3 ways; more folic acid, more iron and less vitamin A -- high levels can be harmful to the fetus.

The study is a meta-analysis, a collection of earlier published studies. Dr. Koren said, “Research has shown, in dribs and drabs, the possible benefits of prenatal multivitamin
'"/>




Page: 1 2 3

Related medicine news :

1. The Safety Of Prenatal Ultrasounds Questioned
2. More Importance To Be Given To Prenatal Nutrition
3. Prenatal exposure to air pollution causes chromosomal damage
4. Prenatal Alcohol Exposure Sets Cognitive Problems After 10 Years
5. Personal Growth and Success Dependent on Prenatal Health
6. Prenatal Test and Miscarriage
7. Prenatal Multivitamins to prevent risk of Brain Tumors In Kids
8. Simple Blood Test may Replace Invasive Prenatal Tests
9. Hope for Noninvasive Prenatal Test
10. New Approach to Routine Prenatal Genetic Testing
11. Harmful Effects Of Glucocorticoids On Newborns Owing To Prenatal Exposure
Post Your Comments:
Other Medicine News:Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 3Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:dLife Launches the World's Largest and Most Comprehensive Online Food and Diabetic Recipe Search Tool 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 1Express Scripts Launches Equity Offering to Finance Acquisition 47588 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 1Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 2Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 4Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 5Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 1Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 2Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 3
Other Medicine Technology:Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5